Guenther G Steger - Medical University of Vienna - Prof

Guenther G Steger

Medical University of Vienna

Prof

Vienna | Austria

Main Specialties: Oncology

Additional Specialties: Breast Cancer

ORCID logohttps://orcid.org/0000-0002-0091-2611

Guenther G Steger - Medical University of Vienna - Prof

Guenther G Steger

Introduction

Primary Affiliation: Medical University of Vienna - Vienna , Austria

Specialties:

Additional Specialties:

Research Interests:

Publications

65Publications

1261Reads

2Profile Views

Therapeutic approaches for protecting bone health in patients with breast cancer.

Breast 2018 Feb 23;37:28-35. Epub 2017 Oct 23.

Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Gaston H. Glock Research Center, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.10.007DOI Listing
February 2018
13 Reads
2.381 Impact Factor

Palbociclib for the treatment of postmenopausal breast cancer - an update.

Expert Opin Pharmacother 2016 14;17(2):255-63. Epub 2016 Jan 14.

a Department of Internal Medicine I/Division of Oncology , Medical University of Vienna , Vienna , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2016.1133590DOI Listing
June 2016
58 Reads
3.534 Impact Factor

Pathological complete remission and long-term outcome-what do we know in 2016?

Lancet Oncol 2016 06 11;17(6):693-694. Epub 2016 May 11.

Department of Internal Medicine I, Breast Health Centre, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30038-9DOI Listing
June 2016
2 Reads
24.690 Impact Factor

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Clin Exp Metastasis 2015 Oct 25;32(7):729-37. Epub 2015 Aug 25.

Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-015-9740-3DOI Listing
October 2015
31 Reads
3.491 Impact Factor

Bevacizumab: no comeback in early breast cancer?

Lancet Oncol 2015 Sep 10;16(9):1001-1003. Epub 2015 Aug 10.

Department of Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, Vienna 1090, Austria.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451500124
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)00124-2DOI Listing
September 2015
13 Reads
24.690 Impact Factor

CDK4/6 inhibitors in luminal breast cancer.

Lancet Oncol 2015 Jan 16;16(1):2-3. Epub 2014 Dec 16.

Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)71188-XDOI Listing
January 2015
25 Reads
24.690 Impact Factor

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.

Breast 2014 Oct 10;23(5):637-43. Epub 2014 Jul 10.

Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria; Department of Pathology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.06.011DOI Listing
October 2014
16 Reads
2.381 Impact Factor

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Breast Care (Basel) 2014 Oct;9(5):344-8

Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000368330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322687PMC
October 2014
35 Reads
0.911 Impact Factor

HER2-positive breast cancer: a new piece of the puzzle.

Lancet Oncol 2014 Jun 2;15(7):668-9. Epub 2014 May 2.

Department of Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70192-5DOI Listing
June 2014
13 Reads
24.690 Impact Factor

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

Breast J 2013 Mar-Apr;19(2):149-55. Epub 2013 Jan 27.

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/tbj.12070
Publisher Site
http://dx.doi.org/10.1111/tbj.12070DOI Listing
September 2013
13 Reads
1.433 Impact Factor

Treatment of Bone Metastases in Patients with Advanced Breast Cancer.

Breast Care (Basel) 2012 Apr 24;7(2):92-98. Epub 2012 Apr 24.

Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000338650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376361PMC
April 2012
10 Reads
0.911 Impact Factor

Dual inhibition of HER2 in breast cancer treatment.

Lancet 2012 Feb 17;379(9816):596-8. Epub 2012 Jan 17.

Department of Surgery, Comprehensive Cancer Centre, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(12)60068-3DOI Listing
February 2012
4 Reads
45.217 Impact Factor

Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer.

Breast Care (Basel) 2011 Dec 15;6(6):427-433. Epub 2011 Dec 15.

Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000335331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290012PMC
December 2011
16 Reads
0.911 Impact Factor

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

Ther Adv Med Oncol 2011 Sep;3(5):233-43

Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834011412656DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169928PMC
September 2011
7 Reads

Breast Cancer: Rank Ligand Inhibition.

Breast Care (Basel) 2010;5(5):320-325. Epub 2010 Oct 15.

Department of Medicine I (Centre for Haematology, Stem Cell Transplantation, Haemostasis and Medical Oncology), Academic Teaching Hospital Elisabethinen, Linz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000321122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132956PMC
October 2010
9 Reads
0.911 Impact Factor

Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.

Breast Care (Basel) 2010;5(3):158-162. Epub 2010 May 27.

Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Medizinische Universität Wien, Österreich.

View Article

Download full-text PDF

Source
http://dx.doi.org/000314214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931054PMC
May 2010
6 Reads
0.911 Impact Factor

Triple-negative breast cancer.

Wien Med Wochenschr 2010 Apr;160(7-8):174-81

Clinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10354-010-0773-6
Publisher Site
http://dx.doi.org/10.1007/s10354-010-0773-6DOI Listing
April 2010
41 Reads

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.

J Bone Miner Res 2010 Mar;25(3):440-6

CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1359/jbmr.090810
Publisher Site
http://dx.doi.org/10.1359/jbmr.090810DOI Listing
March 2010
27 Reads
6.832 Impact Factor

Fighting overtreatment in adjuvant breast cancer therapy.

Lancet 2009 Dec 10;374(9707):2029-2030. Epub 2009 Dec 10.

Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(09)62097-3DOI Listing
December 2009
3 Reads
45.217 Impact Factor

Role of denosumab in breast cancer.

Expert Opin Biol Ther 2009 Sep;9(9):1225-33

Medical University of Vienna, Cancer Centre, Department of Medicine 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712590903146877DOI Listing
September 2009
14 Reads
3.743 Impact Factor

The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.

Breast Care (Basel) 2009 23;4(3):167-176. Epub 2009 Jun 23.

Department of Medicine I and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000223360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931004PMC
June 2009
3 Reads
0.911 Impact Factor

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.

Breast Cancer Res Treat 2009 May 26;115(2):373-80. Epub 2008 Jul 26.

First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10549-008-01
Web Search
http://link.springer.com/10.1007/s10549-008-0132-0
Publisher Site
http://dx.doi.org/10.1007/s10549-008-0132-0DOI Listing
May 2009
6 Reads
3.940 Impact Factor

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.

Cancer Chemother Pharmacol 2008 Oct 7;62(5):903-10. Epub 2008 Feb 7.

First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-008-0682-1DOI Listing
October 2008
15 Reads
2.769 Impact Factor

Factors influencing the time to development of brain metastases in breast cancer.

Breast 2008 Oct 19;17(5):512-6. Epub 2008 May 19.

Department of Radiotherapy and Radiobiology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2008.03.008DOI Listing
October 2008
4 Reads
2.381 Impact Factor

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

J Neurooncol 2007 Dec 8;85(3):311-7. Epub 2007 Jun 8.

Department of Medicine 1 and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-007-9420-5DOI Listing
December 2007
17 Reads
3.070 Impact Factor

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

J Clin Oncol 2007 Sep 6;25(25):3853-8. Epub 2007 Aug 6.

First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.9776DOI Listing
September 2007
4 Reads
18.428 Impact Factor

Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment.

Clin Cancer Res 2007 Aug;13(15 Pt 1):4435-9

First Department of Medicine, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-3050DOI Listing
August 2007
7 Reads
8.722 Impact Factor

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.

Breast Cancer Res Treat 2007 Jul 24;104(1):109-14. Epub 2006 Oct 24.

Department of Internal Medicine I, Division of Clinical Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-006-9397-3DOI Listing
July 2007
39 Reads
3.940 Impact Factor

Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel.

BMC Clin Pharmacol 2007 Jul 18;7. Epub 2007 Jul 18.

First Department of Medicine and Cancer Centre, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1472-6904-7-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939983PMC
July 2007
11 Reads

HER-2-positive breast cancer: hope beyond trastuzumab.

BioDrugs 2007 ;21(2):69-77

Department of Medicine 1 and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00063030-200721020-00001DOI Listing
June 2007
5 Reads
2.989 Impact Factor

Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.

Breast Cancer Res Treat 2007 May 21;102(3):375-81. Epub 2006 Sep 21.

Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, 18-20 Waehringer Guertel, A-1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-006-9342-5DOI Listing
May 2007
2 Reads
3.940 Impact Factor

Trastuzumab in the management of early and advanced stage breast cancer.

Biologics 2007 Mar;1(1):19-31

First Department of Medicine and Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721347PMC
March 2007
49 Reads

Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial.

Cancer Chemother Pharmacol 2006 May 23;57(5):554-8. Epub 2005 Aug 23.

Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, 18-20 Waehringer Guertel, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0092-6DOI Listing
May 2006
9 Reads
2.769 Impact Factor

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.

BMC Cancer 2006 Mar 26;6:81. Epub 2006 Mar 26.

Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-6-81DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435763PMC
March 2006
4 Reads
3.362 Impact Factor

Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.

Cancer Treat Rev 2005 28;31 Suppl 2:S10-6. Epub 2005 Sep 28.

Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, 18-20 Währinger Gürtel, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030573720500141
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2005.08.009DOI Listing
November 2005
21 Reads
7.588 Impact Factor

Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.

Cancer Treat Rev 2005 29;31 Suppl 2:S17-25. Epub 2005 Sep 29.

Belvoir Park Hospital, Hospital Road, Belfast, Northern Ireland, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2005.08.008DOI Listing
November 2005
20 Reads
7.588 Impact Factor

Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience.

Anticancer Drugs 2005 Jul;16(6):617-20

Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200507000-00004DOI Listing
July 2005
4 Reads
1.891 Impact Factor

Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.

Anticancer Drugs 2005 Apr;16(4):441-5

Department of Internal Medicine I, Division of Oncology, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200504000-00011DOI Listing
April 2005
24 Reads
1.891 Impact Factor

Preoperative second-line chemotherapy induces objective responses in primary breast cancer.

Wien Klin Wochenschr 2005 Jan;117(1-2):48-52

Division of Oncology, Department of Internal Medicine I, University Hospital of Vienna, Austria.

View Article

Download full-text PDF

Source
January 2005
5 Reads
0.791 Impact Factor

Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling.

Int J Cancer 2004 Nov;112(2):200-12

VBC-GENOMICS Bioscience Research Inc., Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.20401DOI Listing
November 2004
13 Reads
5.085 Impact Factor

Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.

Support Care Cancer 2004 Sep;12(9):678-81

Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-004-0645-y
Publisher Site
http://dx.doi.org/10.1007/s00520-004-0645-yDOI Listing
September 2004
20 Reads
2.364 Impact Factor

Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study.

J Cancer Res Clin Oncol 2004 Jul;130(7):400-4

Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-004-0559-6DOI Listing
July 2004
47 Reads
3.081 Impact Factor

Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.

Cancer Chemother Pharmacol 2002 Aug 7;50(2):155-9. Epub 2002 Jun 7.

Department of Internal Medicine I/Division of Oncology, University Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-002-0476-9
Publisher Site
http://dx.doi.org/10.1007/s00280-002-0476-9DOI Listing
August 2002
9 Reads
2.769 Impact Factor

Relapsed, poor-prognosis ovarian cancer, individualized, interdisciplinary treatment approach, and quality of life: a case report.

Support Care Cancer 2002 Jan;10(1):81-3

Department of Internal Medicine I, Division of Oncology, University of Vienna, Austria.

View Article

Download full-text PDF

Source
January 2002
6 Reads
2.364 Impact Factor

Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.

Anticancer Drugs 2002 Jan;13(1):67-74

Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200201000-00008DOI Listing
January 2002
40 Reads
1.891 Impact Factor

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.

Am J Kidney Dis 2002 Jan;39(1):48-54

Department of Internal Medicine I, Division of Oncology, the Ludwig Boltzmann Institute for Clinical Oncology, University Hospital of Vienna, Austria.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S027263860265529
Publisher Site
http://dx.doi.org/10.1053/ajkd.2002.29879DOI Listing
January 2002
9 Reads
5.900 Impact Factor

Top co-authors

Rupert Bartsch
Rupert Bartsch

Medical University of Vienna

43
Christoph C Zielinski
Christoph C Zielinski

Medical University of Vienna

32
Michael Gnant
Michael Gnant

Medical University of Vienna

25
Catharina Wenzel
Catharina Wenzel

University of Vienna

25
Ursula Pluschnig
Ursula Pluschnig

Comprehensive Cancer Center of the Medical University of Vienna

23
Margaretha Rudas
Margaretha Rudas

Medical University of Vienna

16
Gottfried J Locker
Gottfried J Locker

Medical University of Vienna

15
Peter Dubsky
Peter Dubsky

Medical University of Vienna

11
Robert M Mader
Robert M Mader

Medical University of Vienna

11
Dagmar Hussian
Dagmar Hussian

Medical University of Vienna

10